Hester Biosciences Limited has informed the Exchange regarding a press release dated May 15, 2026, titled "20250515 Press Release Q4 & FY26".
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Hester Biosciences reported strong Q4 FY26 results with standalone revenue up 22% to Rs 937 million and PAT up 174% to Rs 264 million. For the full year FY26, standalone revenue grew 2% to Rs 2,921 million while PAT jumped 64% to Rs 521 million. Consolidated revenue for FY26 rose 7% to Rs 3,326 million with PAT up 99% to Rs 575 million. EBITDA margin expanded significantly from 19% to 30% on standalone basis. The Board recommended a dividend of Rs 11 per share (110%) for FY26. Poultry Healthcare division drove growth with 41% Q4 increase, while Animal Healthcare continued to face headwinds from government programme delays. The company received marketing licenses for H9N2 Avian Influenza vaccine and capitalized its BSL-3 facility. Statutory auditors issued an unmodified (clean) opinion.
Strong profitability improvement with PAT growth of 64-99% and margin expansion signals operational efficiency gains. The dividend declaration provides immediate shareholder回报. Revenue growth is modest at 2-7% but cost discipline and product mix improvement are driving bottom-line outperformance. The clean audit opinion removes any concern about financial reporting quality.